Subscribe to RSS

DOI: 10.1055/a-2698-3739
The Impact of NOACS versus VKAS on Absolute and Relative Cognitive Function Decline Over Time: A Machine Learning Approach
Authors

Abstract
Background
Atrial fibrillation (AF) is the most common arrhythmia in older adults and is associated with an increased risk of cognitive impairment and dementia, even in patients without prior stroke. Nonvitamin K antagonist oral anticoagulants (NOACs) offer a better safety profile than vitamin K antagonists (VKAs), but their cognitive benefit remains uncertain.
Aim
To assess the impact of NOACs versus VKAs on cognitive decline in elderly AF patients using a machine learning approach.
Methods
This multicenter prospective cohort study included 983 AF outpatients enrolled between 2008 and 2022 at the Geriatrics Department, University of Catanzaro, and the ProMISE Department, University of Palermo. Stroke and bleeding risks were assessed using CHA2DS2-VASc and HAS-BLED scores. Cognitive function was evaluated using the Mini-Mental State Examination (MMSE). Cognitive decline was defined as a decrease in MMSE score between baseline and follow-up. Patients with prior anticoagulant therapy (OAT), severe dementia, or comorbidities affecting cognition were excluded. Multivariable logistic regression and a random forest classifier were used to assess whether anticoagulant type independently predicted cognitive decline. Class imbalance was addressed using both class-weighted learning and the synthetic minority over-sampling technique (SMOTE), with model performance evaluated through repeated stratified cross-validation and threshold optimization.
Results
At baseline, cognitive performance was comparable between groups (p = 0.11). After a mean follow-up of 7.2 ± 3.4 years, MMSE scores declined significantly more in VKA-treated patients (−1.7 vs. −0.3 points, p < 0.001). In logistic regression, NOAC use was independently associated with a lower risk of cognitive decline (odds ratio: 0.322; 95% confidence interval: 0.221–0.469; p < 0.0001). The random forest classifier achieved a mean cross-validated AUC of 0.8719 (standard deviation: 0.0273) and a test-set AUC of 0.880. Threshold adjustment and SMOTE improved sensitivity (recall increased: 0.47–0.84), with a precision–recall AUC of 0.763. Permutation importance analysis identified “OAT” as the top predictor. Predicted probabilities of cognitive decline were significantly higher in VKA users (median = 0.70) than in NOAC users (median = 0.09), confirmed by a Kolmogorov–Smirnov test (KS = 0.385, p < 0.001).
Conclusion
NOAC use is associated with a lower predicted probability of cognitive decline, suggesting potential cognitive benefits over VKAs.
Data Availability Statement
The data and images used in this study are available from the corresponding author upon reasonable request.
Contributors' Statement
S.F., M.D. and G.A. projected the study, coordinated the research group, and contributed to manuscript preparation and revisions, S.F. performed the statistical analysis. G.P., S.S., C.D.M., G.M. and D.D.R. collaborated to collect and process data. D.P., A.S. and A.T. collaborated on supervision and manuscript revisions.
Ethical Approval
All patients gave their informed consent to the study.
Informed Consent
All patients expressed their informed consent to participate in the study and supplied their personal information for publication.
‡ These authors contributed equally to this article.
‡‡ These authors share last authorship.
Publication History
Received: 14 March 2025
Accepted: 11 August 2025
Accepted Manuscript online:
10 September 2025
Article published online:
25 September 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Miyasaka Y, Barnes ME, Gersh BJ. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114 (02) 119-125
- 2 Van Gelder IC, Rienstra M, Bunting KV. et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45 (36) 3314-3414
- 3 Joglar JA, Chung MK, Armbruster AL. et al; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2024; 149 (01) e1-e156
- 4 Wang Y, Guo Y, Qin M. et al; Expert Reviewers. 2024 Chinese Expert Consensus guidelines on the diagnosis and treatment of atrial fibrillation in the elderly, endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): executive summary. Thromb Haemost 2024; 124 (10) 897-911
- 5 Kalantarian S, Ruskin JN. Atrial fibrillation and cognitive decline: phenomenon or epiphenomenon?. Cardiol Clin 2016; 34 (02) 279-285
- 6 Thacker EL, McKnight B, Psaty BM. et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology 2013; 81 (02) 119-125
- 7 Bunch TJ, Weiss JP, Crandall BG. et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm 2010; 7 (04) 433-437
- 8 Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348 (13) 1215-1222
- 9 Poggesi A, Inzitari D, Pantoni L. Atrial fibrillation and cognition: epidemiological data and possible mechanisms. Stroke 2015; 46 (11) 3316-3321
- 10 Diener H-C, Hart RG, Koudstaal PJ, Lane DA, Lip GYH. Atrial fibrillation and cognitive function: JACC review topic of the week. J Am Coll Cardiol 2019; 73 (05) 612-619
- 11 Jefferson AL, Beiser AS, Himali JJ. et al. Low cardiac index is associated with incident dementia and Alzheimer disease: the Framingham Heart Study. Circulation 2015; 131 (15) 1333-1339
- 12 Stefansdottir H, Arnar DO, Aspelund T. et al. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke 2013; 44 (04) 1020-1025
- 13 Knecht S, Oelschläger C, Duning T. et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29 (17) 2125-2132
- 14 Roberti R, Iannone LF, Palleria C. et al. Direct oral anticoagulants: from randomized clinical trials to real-world clinical practice. Front Pharmacol 2021; 12: 684638
- 15 Armentaro G, D'Arrigo G, Bo M. et al. Medium-term and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation. Front Pharmacol 2023; 14: 1210560
- 16 Mongkhon P, Fanning L, Lau WCY. et al. Oral anticoagulant and reduced risk of dementia in patients with atrial fibrillation: a population-based cohort study. Heart Rhythm 2020; 17 (Pt A): 706-713
- 17 Armentaro G, D'Arrigo G, Pastori D. et al. Long-term cognitive function changes with non-vitamin K oral anticoagulants in older patients with atrial fibrillation. a multicenter cohort study. Eur J Clin Invest 2024; 55 (Suppl. 01) e14321
- 18 Daidone M, Ferrantelli S, Tuttolomondo A. Machine learning applications in stroke medicine: advancements, challenges, and future prospectives. Neural Regen Res 2024; 19 (04) 769-773
- 19 Zhou L, Pan S, Wang J, Vasilakos AV. Machine learning on big data: opportunities and challenges. Neurocomputing 2017; 237: 350-361
- 20 Thunell J, Wood K, Wharton W, Joyce G, Ferido P, Zissimopoulos J. Population dementia incidence and direct oral anticoagulant use in a representative population with atrial fibrillation. Neurology 2024; 103 (01) e209568
- 21 Sagris D, Ntaios G, Buckley BJR. et al. Direct oral anticoagulants are associated with lower risk of dementia in patients with atrial fibrillation. Eur J Intern Med 2024; 121: 114-120
- 22 Polidoro A, Stefanelli F, Ciacciarelli M, Pacelli A, Di Sanzo D, Alessandri C. Frailty in patients affected by atrial fibrillation. Arch Gerontol Geriatr 2013; 57 (03) 325-327
- 23 Joosten LPT, van Doorn S, van de Ven PM. et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation 2024; 149 (04) 279-289
- 24 Wang L, Laurentiev J, Yang J. et al. Development and validation of a deep learning model for earlier detection of cognitive decline from clinical notes in electronic health records. JAMA Netw Open 2021; 4 (11) e2135174
- 25 Mele M, Mele A, Imbrici P. et al. Pleiotropic effects of direct oral anticoagulants in chronic heart failure and atrial fibrillation: machine learning analysis. Molecules 2024; 29 (11) 2651
- 26 Danckwardt S, Hentze MW, Kulozik AE. Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J Mol Med (Berl) 2013; 91 (11) 1257-1271
- 27 Álvarez E, Paradela-Dobarro B, Raposeiras-Roubín S, González-Juanatey JR. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium. Br J Clin Pharmacol 2018; 84 (02) 280-291
- 28 Torramade-Moix S, Palomo M, Vera M. et al. Apixaban downregulates endothelial inflammatory and prothrombotic phenotype in an in vitro model of endothelial dysfunction in uremia. Cardiovasc Drugs Ther 2021; 35 (03) 521-532
- 29 Imano H, Kato R, Nomura A. et al. Rivaroxaban attenuates right ventricular remodeling in rats with pulmonary arterial hypertension. Biol Pharm Bull 2021; 44 (05) 669-677
- 30 Zhou Q, Bea F, Preusch M. et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011; 2011: 432080
- 31 Zolotoff C, Puech C, Roche F, Perek N. Effects of intermittent hypoxia with thrombin in an in vitro model of human brain endothelial cells and their impact on PAR-1/PAR-3 cleavage. Sci Rep 2022; 12 (01) 12305
- 32 Arevalo-Rodriguez I, Smailagic N, Roqué-Figuls M. et al. Mini-mental state examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2021; 7 (07) CD010783